title: Aberrant methylation of protocadherin 17 and its clinical significance in patients with prostate cancer after radical prostatectomy.
abstract: BACKGROUND
  Aberrant methylation of protocadherin 17 (PCDH17) has been reported in several human cancers. However, the methylation status of PCDH17 in prostate cancer and its clinical significance remains unclear. The aim of this study was to investigate the methylation status of PCDH17 and its clinical significance in patients with prostate cancer after radical prostatectomy.
  
  
  METHODS
  The methylation status of PCDH17 in 152 prostate cancer tissues and 51 non-tumoral prostate tissues was examined by methylation-specific PCR (MSP). Then the association between PCDH17 methylation and clinicopathologic parameters was analyzed. Kaplan-Meier survival analysis, log-rank test and multivariate Cox proportional hazard model analysis were used to analyze the correlation between PCDH17 methylation and prognosis of patients with prostate cancer.
  
  
  RESULTS
  Our data demonstrated that PCDH17 methylation occurred frequently in prostate cancer. PCDH17 methylation was significantly associated with higher pathological Gleason score (P=0.0315), advanced pathological stage (P=0.0260), higher level of preoperative PSA (P=0.0354), positive angiolymphatic invasion (P=0.0461), positive lymph node metastasis (P=0.0362), and biochemical recurrence (BCR) (P=0.0018). In addition, PCDH17 methylation was an independent predictor of poor biochemical recurrence-free (BCR-free) survival and overall survival for patients with prostate cancer.
  
  
  CONCLUSIONS
  PCDH17 methylation is a frequent tumor-specific event in prostate cancer, and is significantly correlated with shorter BCR-free survival and overall survival of patients with prostate cancer after radical prostatectomy. PCDH17 methylation in tumor samples after radical prostatectomy may be used as an independent prognostic biomarker.
authors.affiliation: Department of Urology, Xuzhou Cancer Hospital (Affiliated Xuzhou Hospital, Jiangsu University), Xuzhou, China (mainland).
authors.forename: Ying-Li
authors.initials: YL
authors.lastname: Lin
authors.affiliation: Department of Spine Surgery, Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China (mainland).
authors.forename: Pei-Gen
authors.initials: PG
authors.lastname: Xie
authors.affiliation: Department of Urology, Affiliated Hospital, Hebei University of Engineering, Handan, China (mainland).
authors.forename: Li
authors.initials: L
authors.lastname: Wang
authors.affiliation: Department of Urology, Third Hospital, Hebei Medical University, Shijiazhuang, China (mainland).
authors.forename: Jian-Guo
authors.initials: JG
authors.lastname: Ma
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000235:genetics*; D015820:Cadherins / Q000235:genetics / Q000378:metabolism; D002681:China; D019175:DNA Methylation / Q000235:genetics*; D017931:DNA Primers / Q000235:genetics; D018572:Disease-Free Survival; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D016133:Polymerase Chain Reaction; D016016:Proportional Hazards Models; D017430:Prostate-Specific Antigen / Q000097:blood; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000601:surgery*
chemical_list: D014408:Biomarkers, Tumor; D015820:Cadherins; D017931:DNA Primers; C529349:PCDH17 protein, human; D017430:Prostate-Specific Antigen
references.citation: Curr Urol. 2013 Aug;7(1):1-6
references.pmid: 24917748
references.citation: Cancer Biol Ther. 2006 Aug;5(8):993-1001
references.pmid: 16775427
references.citation: J Exp Clin Cancer Res. 2014 Apr 09;33:31
references.pmid: 24716822
references.citation: Cancer J. 2002 Nov-Dec;8(6):440-4
references.pmid: 12500852
references.citation: PLoS One. 2014 Mar 24;9(3):e92815
references.pmid: 24664224
references.citation: Eur J Cancer Prev. 2012 Nov;21(6):569-75
references.pmid: 22273848
references.citation: Cancer Lett. 2014 Jan 28;342(2):248-56
references.pmid: 22391123
references.citation: Asian J Androl. 2013 May;15(3):350-3
references.pmid: 23603922
references.citation: CA Cancer J Clin. 2013 Jan;63(1):11-30
references.pmid: 23335087
references.citation: Med Sci Monit. 2012 Apr;18(4):CR260-4
references.pmid: 22460098
references.citation: Med Sci Monit. 2011 Feb;17(2):CR104-9
references.pmid: 21278686
references.citation: Biochim Biophys Acta. 2012 Feb;1823(2):298-305
references.pmid: 22206871
references.citation: Med Sci Monit. 2014 May 19;20:818-24
references.pmid: 24835144
references.citation: Urol Clin North Am. 2014 May;41(2):257-66
references.pmid: 24725488
references.citation: Am J Case Rep. 2012;13:206-8
references.pmid: 23569530
references.citation: Nat Rev Cancer. 2014 Feb;14(2):121-34
references.pmid: 24442140
references.citation: Oncogene. 2008 Aug 7;27(34):4657-65
references.pmid: 18408767
references.citation: Cancer Lett. 2014 Jan 28;342(2):264-74
references.pmid: 22198482
references.citation: Carcinogenesis. 2010 Jun;31(6):1027-36
references.pmid: 20200074
references.citation: J Urol. 1980 Aug;124(2):223-5
references.pmid: 6995622
references.citation: J Exp Clin Cancer Res. 2005 Jun;24(2):175-80
references.pmid: 16110748
references.citation: J Exp Clin Cancer Res. 2013 Aug 16;32(1):56
references.pmid: 23958433
references.citation: Genes Chromosomes Cancer. 2013 Nov;52(11):1030-41
references.pmid: 23929756
references.citation: Biomed Res Int. 2014;2014:890697
references.pmid: 24877145
references.citation: J Pathol. 2013 Jan;229(1):62-73
references.pmid: 22926751
references.citation: Oncol Rep. 2012 Nov;28(5):1785-91
references.pmid: 22941331
references.citation: Cancer Res. 2006 May 1;66(9):4617-26
references.pmid: 16651412
references.citation: J Int Med Res. 2014 Apr;42(2):292-9
references.pmid: 24567353
references.citation: J Int Med Res. 2014 Feb;42(1):35-41
references.pmid: 24366498
references.citation: Cell Adh Migr. 2011 Mar-Apr;5(2):97-105
references.pmid: 21173574
references.citation: Histol Histopathol. 2012 Feb;27(2):217-24
references.pmid: 22207556
references.citation: J Int Med Res. 2012;40(6):2117-23
references.pmid: 23321168
references.citation: Epigenetics. 2011 Sep 1;6(9):1120-30
references.pmid: 21847011
references.citation: Genes Chromosomes Cancer. 2011 Mar;50(3):154-66
references.pmid: 21213369
references.citation: J Int Med Res. 2013 Feb;41(1):48-54
references.pmid: 23569129
references.citation: Prim Care. 2014 Jun;41(2):355-70
references.pmid: 24830612
references.citation: Cancer Causes Control. 2013 Sep;24(9):1615-41
references.pmid: 23797237
references.citation: Nurs Times. 2014 Feb 26-Mar 4;110(9):12-5
references.pmid: 24754104